Rob Armstrong is Chief Executive Officer and Co-founder of Boston Pharmaceuticals, with over 20 years of experience in biopharmaceutical research and development. He has been involved in the discovery and clinical development of programs across multiple disease areas.
Rob established and led the small molecule R&D organization at Amgen in Thousand Oaks, CA. He later co-led research at Lilly as Vice President of Global Medicinal Chemistry, served as Head of the Translational Medicine group Chorus, and was Vice President of Global External R&D. He also served on both the Scientific and Investment Advisory Boards of Lilly BioVentures.
Before entering the pharmaceutical industry, Rob was a tenured professor of chemistry and biochemistry at the University of California, Los Angeles (UCLA). He holds a Bachelor’s degree in Chemistry from UCSD, a PhD in Chemistry from CSU, and completed a NIH postdoctoral fellowship at Harvard University.
Rob currently serves as an advisor to Gelesis and sits on the board of directors of several early-stage biotechnology companies, including Curza Therapeutics, Cloud Pharmaceuticals, Entrega Bio, and Artax Biopharma.
